{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:37:07Z","timestamp":1793104627013,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40273-026-01649-6","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:14:50Z","timestamp":1785777290000},"page":"1369-1381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["External Validation of SELECT Trial-Derived Cardiovascular Risk Equations in a UK Population with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes"],"prefix":"10.1007","volume":"44","author":[{"given":"Felice","family":"Gragnano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6431-8307","authenticated-orcid":false,"given":"Martin","family":"B\u00f8g","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Bo","family":"Bojesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milana","family":"Ivkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"L\u00fcbker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Resham","family":"Baruah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Whitaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nia C.","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iestyn","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffan","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Weeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Michael","family":"Lincoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"1649_CR1","unstructured":"World Health Organization. Obesity and overweight. 2024."},{"key":"1649_CR2","unstructured":"World Obesity Federation. World Obesity Atlas 2023. 2023. https:\/\/data.worldobesity.org\/publications\/?cat=19."},{"issue":"1","key":"1649_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12963-020-00219-y","volume":"18","author":"MS Felisbino-Mendes","year":"2020","unstructured":"Felisbino-Mendes MS, Cousin E, Malta DC, Machado \u00cdE, Ribeiro ALP, Duncan BB, et al. The burden of non-communicable diseases attributable to high BMI in Brazil, 1990\u20132017: findings from the Global Burden of Disease Study. Popul Health Metrics. 2020;18(1):18.","journal-title":"Popul Health Metrics"},{"key":"1649_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.metabol.2018.10.011","volume":"92","author":"C Koliaki","year":"2019","unstructured":"Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019;92:98\u2013107.","journal-title":"Metabolism"},{"key":"1649_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102782","author":"N Alfaris","year":"2024","unstructured":"Alfaris N, Waldrop S, Johnson V, Boaventura B, Kendrick K, Stanford FC. GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review. eClinicalMedicine. 2024. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102782.","journal-title":"eClinicalMedicine"},{"issue":"1","key":"1649_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12170-025-00761-0","volume":"19","author":"B Suter","year":"2025","unstructured":"Suter B, Rhodes A, Bigeh A, Frommeyer T, Mehta LS. The role of GLP-1RA medications in medical weight loss and the positive impacts on lipid management. Curr Cardiovasc Risk Rep. 2025;19(1):11.","journal-title":"Curr Cardiovasc Risk Rep"},{"issue":"11","key":"1649_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000047994","volume":"105","author":"N Ahmad","year":"2026","unstructured":"Ahmad N, Alruwayyes A, Alarjani A, Tawhari A, Aldosri A, Alahmari A, et al. GLP-1 receptor agonists for weight loss: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2026;105(11):e47994.","journal-title":"Medicine (Baltimore)"},{"issue":"24","key":"1649_CR8","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun Helen M, Deanfield J, Emerson Scott S, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New Engl J Med. 2023;389(24):2221\u201332.","journal-title":"New Engl J Med"},{"key":"1649_CR9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000538577","volume":"17","author":"J Deanfield","year":"2024","unstructured":"Deanfield J, Lingvay I, Kahn SK, Emerson SS, Plutzky J, Colhoun H, et al. Relevance of body weight and weight change on cardiovascular benefit with semaglutide: a pre-specified analysis of the SELECT trial (GC4.351). Obes Facts. 2024;17:7\u2013515.","journal-title":"Obes Facts"},{"issue":"5","key":"1649_CR10","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1111\/dom.16271","volume":"27","author":"J Pearson-Stuttard","year":"2025","unstructured":"Pearson-Stuttard J, Chan MS, Holloway S, Sommer Matthiessen K, Thompson A, Capucci S. Estimating healthcare resource utilisation and cardiovascular events in people with high body mass index and established cardiovascular disease. Diabetes Obes Metab. 2025;27(5):2690\u20137.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1649_CR11","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1177\/2047487320925639","volume":"28","author":"CW le Roux","year":"2021","unstructured":"le Roux CW, Hartvig NV, Haase CL, Nordsborg RB, Olsen AH, Satylganova A. Obesity, cardiovascular risk and healthcare resource utilization in the UK. Eur J Prev Cardiol. 2021;28(11):1235\u201341.","journal-title":"Eur J Prev Cardiol"},{"issue":"7","key":"1649_CR12","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00592-023-02045-8","volume":"60","author":"L Xinyu","year":"2023","unstructured":"Xinyu L, Fang L, et al. Prediction of complications in health economic models of type 2 diabetes: a review of methods used. Acta Diabetol. 2023;60(7):861\u201379.","journal-title":"Acta Diabetol"},{"issue":"10","key":"1649_CR13","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s40273-020-00941-3","volume":"38","author":"S Lopes","year":"2020","unstructured":"Lopes S, Johansen P, Lamotte M, McEwan P, Olivieri A-V, Foos V. External validation of the core obesity model to assess the cost-effectiveness of weight management interventions. Pharmacoeconomics. 2020;38(10):1123\u201333.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"1649_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/osp4.495","volume":"7","author":"S Lopes","year":"2021","unstructured":"Lopes S, Meincke HH, Lamotte M, Olivieri A-V, Lean MEJ. A novel decision model to predict the impact of weight management interventions: the core obesity model. Obes Sci Pract. 2021;7(3):269\u201380.","journal-title":"Obes Sci Pract"},{"key":"1649_CR15","unstructured":"Excellence NIfH, Care. Liraglutide for managing overweight and obesity | Guidance | NICE. 2020."},{"key":"1649_CR16","unstructured":"National Institute for H, Care E. Semaglutide for managing overweight and obesity | Guidance | NICE. 2023."},{"issue":"2 Pt 1","key":"1649_CR17","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/S0002-8703(00)90236-9","volume":"139","author":"RB D'Agostino","year":"2000","unstructured":"D\u2019Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PW, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J. 2000;139(2 Pt 1):272\u201381.","journal-title":"Am Heart J"},{"key":"1649_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-025-01580-2","author":"M B\u00f8g","year":"2026","unstructured":"B\u00f8g M, Bojesen AB, Emerson S, Ivkovic M, Jenkins NC, L\u00fcbker C, et al. Development of cardiovascular risk equations in people with overweight or obesity and established cardiovascular disease without diabetes based on the SELECT Trial. Pharmacoeconomics. 2026. https:\/\/doi.org\/10.1007\/s40273-025-01580-2.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"1649_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/ejcts\/ezy180","volume":"54","author":"SW Grant","year":"2018","unstructured":"Grant SW, Collins GS, Nashef SAM. Statistical Primer: developing and validating a risk prediction model. Eur J Cardio-Thorac Surg. 2018;54(2):203\u20138.","journal-title":"Eur J Cardio-Thorac Surg"},{"issue":"3","key":"1649_CR20","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ije\/dyv098","volume":"44","author":"E Herrett","year":"2015","unstructured":"Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827\u201336.","journal-title":"Int J Epidemiol"},{"issue":"749","key":"1649_CR21","doi-asserted-by":"publisher","first-page":"e854","DOI":"10.3399\/BJGP.2024.0017","volume":"74","author":"SA Sullivan","year":"2024","unstructured":"Sullivan SA, Morris R, Kounali D, Kessler D, Hamilton W, Lewis G, et al. External validation of a prognostic model to improve prediction of psychosis: a retrospective cohort study in primary care. Br J Gen Pract. 2024;74(749):e854\u201360.","journal-title":"Br J Gen Pract"},{"issue":"1","key":"1649_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-073455","volume":"14","author":"YM Nakao","year":"2024","unstructured":"Nakao YM, Nadarajah R, Shuweihdi F, Nakao K, Fuat A, Moore J, et al. Predicting incident heart failure from population-based nationwide electronic health records: protocol for a model development and validation study. BMJ Open. 2024;14(1):e073455.","journal-title":"BMJ Open"},{"issue":"4","key":"1649_CR23","first-page":"1","volume":"12","author":"B Guthrie","year":"2024","unstructured":"Guthrie B, Rogers G, Livingstone S, Morales DR, Donnan P, Davis S, et al. The implications of competing risks and direct treatment disutility in cardiovascular disease and osteoporotic fracture: risk prediction and cost effectiveness analysis. Health Soc Care Deliv Res. 2024;12(4):1\u2013275.","journal-title":"Health Soc Care Deliv Res"},{"issue":"1","key":"1649_CR24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/mpr.329","volume":"20","author":"MJ Azur","year":"2011","unstructured":"Azur MJ, Stuart EA, Frangakis C, Leaf PJ. Multiple imputation by chained equations: what is it and how does it work? Int J Methods Psychiatr Res. 2011;20(1):40\u20139.","journal-title":"Int J Methods Psychiatr Res"},{"issue":"2","key":"1649_CR25","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/bimj.201300188","volume":"56","author":"M O'Kelly","year":"2014","unstructured":"O\u2019Kelly M. Multiple imputation and its application. Biom J. 2014;56(2):352\u20133.","journal-title":"Biom J"},{"issue":"1","key":"1649_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/096228029900800102","volume":"8","author":"JL Schafer","year":"1999","unstructured":"Schafer JL. Multiple imputation: a primer. Stat Methods Med Res. 1999;8(1):3\u201315.","journal-title":"Stat Methods Med Res"},{"key":"1649_CR27","volume-title":"Multiple imputation for nonresponse in surveys","author":"DB Rubin","year":"2004","unstructured":"Rubin DB. Multiple imputation for nonresponse in surveys. John Wiley & Sons; 2004."},{"issue":"18","key":"1649_CR28","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1093\/eurheartj\/ehac056","volume":"43","author":"SHJ Hageman","year":"2022","unstructured":"Hageman SHJ, McKay AJ, Ueda P, Gunn LH, Jernberg T, Hagstr\u00f6m E, et al. Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm. Eur Heart J. 2022;43(18):1715\u201327.","journal-title":"Eur Heart J"},{"issue":"1","key":"1649_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s41512-023-00163-z","volume":"7","author":"KT Tanner","year":"2023","unstructured":"Tanner KT, Keogh RH, Coupland CAC, Hippisley-Cox J, Diaz-Ordaz K. Dynamic updating of clinical survival prediction models in a changing environment. Diagn Progn Res. 2023;7(1):24.","journal-title":"Diagn Progn Res"},{"issue":"16","key":"1649_CR30","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009217","volume":"7","author":"L Kaasenbrood","year":"2018","unstructured":"Kaasenbrood L, Bhatt DL, Dorresteijn JAN, Wilson PWF, D\u2019Agostino RB Sr., Massaro JM, et al. Estimated life expectancy without recurrent cardiovascular events in patients with vascular disease: the SMART-REACH model. J Am Heart Assoc. 2018;7(16):e009217.","journal-title":"J Am Heart Assoc"},{"key":"1649_CR31","unstructured":"Centers for Disease Control and Prevention National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. 2024. https:\/\/www.cdc.gov\/nchs\/nhanes\/index.htm."},{"key":"1649_CR32","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ijcard.2020.09.053","volume":"325","author":"CCV Klooster","year":"2021","unstructured":"Klooster CCV, Bhatt DL, Steg PG, Massaro JM, Dorresteijn JAN, Westerink J, et al. Predicting 10-year risk of recurrent cardiovascular events andcardiovascular interventions in patients with established cardiovascular disease: results from UCC-SMART and REACH. Int J Cardiol. 2021;325:140\u20138.","journal-title":"Int J Cardiol"},{"issue":"12","key":"1649_CR33","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1136\/heartjnl-2013-303640","volume":"99","author":"JA Dorresteijn","year":"2013","unstructured":"Dorresteijn JA, Visseren FL, Wassink AM, Gondrie MJ, Steyerberg EW, Ridker PM, et al. Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score. Heart. 2013;99(12):866\u201372.","journal-title":"Heart"},{"issue":"18","key":"1649_CR34","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1093\/eurjpc\/zwaa098","volume":"28","author":"KK Poppe","year":"2022","unstructured":"Poppe KK, Wells S, Jackson R, Doughty RN, Kerr AJ. Predicting cardiovascular disease risk across the atherosclerotic disease continuum. Eur J Prev Cardiol. 2022;28(18):2010\u20137.","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"1649_CR35","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/eurjpc\/zwad314","volume":"31","author":"A Holt","year":"2024","unstructured":"Holt A, Batinica B, Liang J, Kerr A, Crengle S, Hudson B, et al. Development and validation of cardiovascular risk prediction equations in 76 000 people with known cardiovascular disease. Eur J Prev Cardiol. 2024;31(2):218\u201327.","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"1649_CR36","doi-asserted-by":"publisher","first-page":"073455","DOI":"10.1136\/bmjopen-2023-073455","volume":"14","author":"YM Nakao","year":"2024","unstructured":"Nakao YM, Nadarajah R, Shuweihdi F, Nakao K, Fuat A, Moore J, et al. Predicting incident heart failure from population-based nationwide electronic health records: protocol for a model development and validation study. BMJ Open. 2024;14(1):073455.","journal-title":"BMJ Open"},{"issue":"1","key":"1649_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12963-023-00302-0","volume":"21","author":"SI Shiekh","year":"2023","unstructured":"Shiekh SI, Harley M, Ghosh RE, Ashworth M, Myles P, Booth HP, et al. Completeness, agreement, and representativeness of ethnicity recording in the United Kingdom\u2019s Clinical Practice Research Datalink (CPRD) and linked Hospital Episode Statistics (HES). Popul Health Metrics. 2023;21(1):3.","journal-title":"Popul Health Metrics"},{"issue":"1","key":"1649_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12872-023-03209-8","volume":"23","author":"S Livingstone","year":"2023","unstructured":"Livingstone S, Morales DR, Fleuriot J, Donnan PT, Guthrie B. External validation of the QLifetime cardiovascular risk prediction tool: population cohort study. BMC Cardiovasc Disord. 2023;23(1):1\u201312.","journal-title":"BMC Cardiovasc Disord"},{"issue":"2","key":"1649_CR39","doi-asserted-by":"publisher","first-page":"BJGPO.2020.0117","DOI":"10.3399\/BJGPO.2020.0117","volume":"5","author":"A Morgan","year":"2021","unstructured":"Morgan A, Sinnott S-J, Smeeth L, Minassian C, Quint J. Concordance in the recording of stroke across UK primary and secondary care datasets: a population-based cohort study. BJGP Open. 2021;5(2):BJGPO.2020.0117.","journal-title":"BJGP Open"},{"key":"1649_CR40","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2147\/CLEP.S319245","volume":"13","author":"R Persson","year":"2021","unstructured":"Persson R, Sponholtz T, Vasilakis-Scaramozza C, Hagberg KW, Williams T, Kotecha D, et al. Quality and completeness of myocardial infarction recording in Clinical Practice Research Datalink Aurum. Clin Epidemiol. 2021;13:745\u201353.","journal-title":"Clin Epidemiol"},{"key":"1649_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2025.133028","volume":"423","author":"V De Sio","year":"2025","unstructured":"De Sio V, Gragnano F, Capolongo A, Guarnaccia N, Maddaluna P, Acerbo V, et al. Eligibility for and practical implications of Semaglutide in overweight and obese patients with acute coronary syndrome. Int J Cardiol. 2025;423:133028.","journal-title":"Int J Cardiol"},{"issue":"1","key":"1649_CR42","doi-asserted-by":"publisher","first-page":"17552","DOI":"10.1038\/s41598-017-17784-2","volume":"7","author":"PE Puddu","year":"2017","unstructured":"Puddu PE, Piras P, Kromhout D, Tolonen H, Kafatos A, Menotti A. Re-calibration of coronary risk prediction: an example of the Seven Countries Study. Sci Rep. 2017;7(1):17552.","journal-title":"Sci Rep"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01649-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01649-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01649-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:05:21Z","timestamp":1793102721000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01649-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1649"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01649-6","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MB, ABB, MI, CL, FF, RB, JW\n                      and\n                      PW\n                      are employees of Novo Nordisk.\n                      NJ\n                      ,\n                      IL\n                      and\n                      SH\n                      are employees of Health Economics and Outcomes Research Ltd. Health Economics and Outcomes Research Ltd. received fees from Novo Nordisk in relation to this study.\n                      AML\n                      has received research grants paid to his institution from AbbVie Inc., AstraZeneca, CSL Behring, Eli Lilly and Company, Esperion Therapeutics, Inc., and Novartis and has served as a consultant for Akebia Therapeutics Inc, Alnylam Pharmaceuticals Inc., Ardelyx, Eli Lilly and Company, FibroGen, GlaxoSmithKline, Intarcia, Medtronic Vascular, Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk, Provention Bio, Entity, and ReCor Medica.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was approved by the CPRD Independent Scientific Advisory Committee for Medicines & Healthcare products Regulatory Agency database research (protocol number 22_002360).","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated during and\/or analysed during the current study are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MB\n                      ,\n                      ABB\n                      and\n                      MI\n                      conceptualised and designed the study.\n                      NJ\n                      ,\n                      IL\n                      and\n                      SH\n                      were responsible for data analysis. All authors contributed to interpretation of the results, reviewed the manuscript, and approved the final manuscript for publication.","order":4,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}